Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1994 1
1996 3
1997 23
1998 64
1999 66
2000 70
2001 70
2002 81
2003 105
2004 128
2005 96
2006 120
2007 102
2008 101
2009 99
2010 111
2011 95
2012 100
2013 102
2014 109
2015 119
2016 118
2017 133
2018 122
2019 105
2020 143
2021 139
2022 162
2023 181
2024 72

Text availability

Article attribute

Article type

Publication date

Search Results

2,694 results

Results by year

Filters applied: . Clear all
Page 1
Donepezil for dementia due to Alzheimer's disease.
Birks JS, Harvey RJ. Birks JS, et al. Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3. Cochrane Database Syst Rev. 2018. PMID: 29923184 Free PMC article. Review.
BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. ...Donepezil was also associated with better function measured with the Alzheimer's Disease Cooperative Study activities of daily living s …
BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. ...Donepezil was al …
Donepezil for dementia due to Alzheimer's disease.
Govind N. Govind N. Br J Community Nurs. 2020 Mar 2;25(3):148-149. doi: 10.12968/bjcn.2020.25.3.148. Br J Community Nurs. 2020. PMID: 32160022 Review. No abstract available.
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Marucci G, et al. Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. Neuropharmacology. 2021. PMID: 33035532 Free article. Review.
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations. ...The first ChE-I licensed for symptomatic treatment of AD was tacrine. …
Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive declin …
Cholinesterase inhibitors for Alzheimer's disease.
Birks J. Birks J. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD005593. doi: 10.1002/14651858.CD005593. Cochrane Database Syst Rev. 2006. PMID: 16437532 Free PMC article. Review.
The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). ...Fewer patients suffer adv …
The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of eac …
Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis.
Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Guo J, et al. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. Brain Behav. 2020. PMID: 32914577 Free PMC article.
INTRODUCTION: Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burdening patients, families, and aging societies worldwide. ...The combination therapy was more effective in improving cognition (mean difference …
INTRODUCTION: Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burden …
Alzheimer's disease.
Blennow K, de Leon MJ, Zetterberg H. Blennow K, et al. Lancet. 2006 Jul 29;368(9533):387-403. doi: 10.1016/S0140-6736(06)69113-7. Lancet. 2006. PMID: 16876668 Review.
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding of the molecular pathogenesis of the hallmarks of the disease--ie, plaques, composed of amyloid beta (Abeta), and tangles, composed o …
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding …
Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.
Zhang N, Gordon ML. Zhang N, et al. Clin Interv Aging. 2018 Oct 11;13:1963-1970. doi: 10.2147/CIA.S159920. eCollection 2018. Clin Interv Aging. 2018. PMID: 30349215 Free PMC article. Review.
Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in China. ...We include Chinese clinical trials and other well-designed studies investigating donepezil or using donepezil as a p …
Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in …
Donepezil for dementia due to Alzheimer's disease.
Birks J, Harvey RJ. Birks J, et al. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. doi: 10.1002/14651858.CD001190.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437430 Updated. Review.
BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. ...OBJECTIVES: The objective of this review is to assess whether donepezil improves the well-being of patients with dementia due to Alzheimer' …
BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. ...OBJECTIVES: The objecti …
Donepezil for dementia due to Alzheimer's disease.
Birks JS, Harvey R. Birks JS, et al. Cochrane Database Syst Rev. 2003;(3):CD001190. doi: 10.1002/14651858.CD001190. Cochrane Database Syst Rev. 2003. PMID: 12917900 Updated. Review.
BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. ...However, some (like tacrine) are associated with adverse effects such as hepatotoxicity, but donepezil (E2020, Aricept) is safer. OBJECTIVES: The objective …
BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. ...However, some (like tac …
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Veroniki AA, Ashoor HM, Rios P, Seitidis G, Stewart L, Clarke M, Tudur-Smith C, Mavridis D, Hemmelgarn BR, Holroyd-Leduc J, Straus SE, Tricco AC. Veroniki AA, et al. BMJ Open. 2022 Apr 26;12(4):e053012. doi: 10.1136/bmjopen-2021-053012. BMJ Open. 2022. PMID: 35473731 Free PMC article.
OBJECTIVE: To examine the comparative efficacy and safety of cognitive enhancers by patient characteristics for managing Alzheimer's dementia (AD). DESIGN: Systematic review and individual patient data (IPD) network meta-analysis (NMA) based on our previously …
OBJECTIVE: To examine the comparative efficacy and safety of cognitive enhancers by patient characteristics for managing Alzheimer' …
2,694 results